UNSPSC 51273303: Pinolcaine

This classification denotes an anesthetic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S0U059XF2E. European Medicines Agency schedules Pinolcaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09855MIG. Pinolcaine generally arises in the molecular formula C23H29NO2.

UNSPSC 51273303 Pinolcaine is a Commodity code that captures state and local procurement of local anesthetics and related pharmaceutical agents for medical use. Based on recent activity, the code reflects actual purchasing of naloxone and drug deactivation systems for community health programs, generic multi-source pharmaceuticals and over-the-counter products for distribution across state and local health facilities, and exploratory procurement of direct-to-manufacturer prescription fulfillment programs. Issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multi-state cooperative purchasing alliances serving state departments and participating municipalities and health systems (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, administered by Minnesota Department of Administration).

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly delivery to the Seminole County Community Health Building, response due July 26, 2023. The Texas HHS Commission posted RFI HHS0017013 on April 3, 2026, requesting vendor information on direct-to-manufacturer prescription program capabilities and capacity to contract outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Department of Administration, through MMCAP, issued RFP S1070000015802 on January 20, 2026, establishing multiple contracts for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson), with proposals due March 26, 2026, and contract awards effective July 1, 2026. The MMCAP procurement requires manufacturers to certify compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act, maintain relationships with at least two of three authorized wholesalers, and submit pricing in multiple formats including flat price, net price, and WAC-minus structures.